In January 2023, it was announced that Zimmer Biomet would acquire Embody, Inc -- a regenerative medicine company organized around development to in-use condition of implantable medical devices to address unmet needs in soft tissue restoration and regeneration. Fairly active in recent years in the SBIR arena across several agencies, Embody's core technology and expertise is in nanoscale material design and fabrication. Implantable materials developed by the firm have the potential to direct and modulate the body's own healing response, resulting in faster recovery, better outcomes and improved functionality, and return to pre-injury performance for the patient. With a focus currently on product applications for the Achilles tendon and Rotator Cuff repair, the longer term goal of management is to develop an engineered anterior cruciate ligament (ACL) replacement. Treatment options for these indications currently are less than optimum often resulting in significant patient disability due to extended recovery times, and failure to recover pre-injury performance, strength, and function. The firm uniquely qualified team of scientists and engineers bring to the task a combination of biofabrication and collagen science expertise collectively enabling use of advanced manufacturing methods, development of novel biomaterials and used of advanced cellular remodeling.
